Radionuclide-Drug Conjugates (RDCs) are core carriers for the integrated diagnosis and treatment of tumors, enabling simultaneous precise diagnosis and tumor killing. Among them, peptide-based RDCs have become an important direction for cancer treatment due to their high matching degree between half-life and radionuclides, excellent targeting, and good safety.
